Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against advanced hepatocellular carcinoma (HCC). Combination treatments comprising angiogenesis inhibitors plus ICIs are promising options for improving cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Takayuki, Kato, Yu, Ozawa, Yoichi, Kodama, Kotaro, Ito, Junichi, Ichikawa, Kenji, Yamada, Kazuhiko, Hori, Yusaku, Tabata, Kimiyo, Takase, Kazuma, Matsui, Junji, Funahashi, Yasuhiro, Nomoto, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272102/
https://www.ncbi.nlm.nih.gov/pubmed/30447042
http://dx.doi.org/10.1111/cas.13806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272102/
https://www.ncbi.nlm.nih.gov/pubmed/30447042
http://dx.doi.org/10.1111/cas.13806

Ejemplares similares